Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
2(15%)
Results Posted
86%(6 trials)
Terminated
2(15%)

Phase Distribution

Ph not_applicable
3
23%
Ph phase_1
1
8%
Ph phase_2
6
46%
Ph phase_3
1
8%
Ph phase_4
2
15%

Phase Distribution

1

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
6(46.2%)
Phase 3Large-scale testing
1(7.7%)
Phase 4Post-market surveillance
2(15.4%)
N/ANon-phased studies
3(23.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

63.6%

7 of 11 finished

Non-Completion Rate

36.4%

4 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(7)
Terminated(4)

Detailed Status

Completed7
Withdrawn2
Terminated2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
77.8%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 26 (46.2%)
Phase 31 (7.7%)
Phase 42 (15.4%)
N/A3 (23.1%)

Trials by Status

withdrawn215%
terminated215%
completed754%
recruiting215%

Recent Activity

2 active trials
Showing 5 of 13
recruitingphase_2

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

NCT07481734
completedphase_2

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

NCT02572323
completedphase_2

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

NCT03375788
recruitingphase_2

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

NCT06554717
completedphase_4

Body Composition and Adipose Tissue in HIV

NCT03226821
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07481734Phase 2

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

Recruiting
NCT02572323Phase 2

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

Completed
NCT03375788Phase 2

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

Completed
NCT06554717Phase 2

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

Recruiting
NCT03226821Phase 4

Body Composition and Adipose Tissue in HIV

Completed
NCT00608023Phase 3

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Completed
NCT01388920Phase 2

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

Terminated
NCT02196831Not Applicable

Tesamorelin Effects on Liver Fat and Histology in HIV

Completed
NCT02931474Phase 2

Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia

Withdrawn
NCT01591902Phase 4

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

Terminated
NCT01263717Not Applicable

Effects of Growth Hormone Releasing Hormone in HIV

Completed
NCT01632592Not Applicable

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

Withdrawn
NCT02012556Phase 1

Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13